Stoyanova Lab
  • Home
  • Research
  • Our Group
  • Alumni
  • Publications
  • News
  • Join Our Team
  • Donate
    • Sponsors
  • Contact
Stoyanova Lab
  • Home
  • Research
  • Our Group
  • Alumni
  • Publications
  • News
  • Join Our Team
  • Donate
    • Sponsors
  • Contact

UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas

January 22, 2024

Stoyanova lab is excited to share our new publication on Cell Reports Medicine on revealing mechanisms of UCHL1 function in regulating the progression of neuroendocrine carcinomas and identifying UCHL1 as a therapeutic target and potential molecular indicator for diagnosing and monitoring treatment responses in these malignancies.

Congratulations!

Link to Publication: https://www.cell.com/cell-reports-medicine/pdf/S2666-3791(23)00610-9.pdf

January 22, 2024

NewsUCLA

FacebookXPinterestRedditDeliciousWhatsappEmail
  • PreviousHigh expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker

  • NextBiofabrication of prostate cancer-like 3D models utilizing co-axial hydrogel spinning

Related Posts ...

Exciting news: Dr. Hyeonji Hwang, a postdoctoral fellow at Dr. Stoyanova’s Lab in UCLA, awarded the Prostate Cancer Research Program Early Investigator Research Award by the US Department of Defense (DOD) for the project titled “Targeting Trop2-Mediated Ferroptosis as a New Therapy for Advanced Prostate Cancer”

News, UCLA

Exciting News: Dr. Tanya Stoyanova receives 2025 Neuroendocrine Tumor Research Foundation Pilot Award

News, UCLA

Logo

ADDRESS

Los Angeles
CA 90095, USA
tstoyanova@mednet.ucla.edu

+1 (310) 825 0955

QUICK LINKS

  • UCLA
  • UCLA Health
  • Positions Available
© Stoyanova Lab. All Rights Reserved. | admin login